Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics Incorporated announces the acceptance of three posters with preclinical data on its highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor, and next-generation CDK4/6 inhibitor for presentation at the AACR Annual Meeting 2024. The Company's Chief Scientific Officer, Peggy Scherle, looks forward to sharing data on the preclinical characterization of PRT7732, the lead oral SMARCA2 degrader, which is set to enter Phase 1 clinical development in the second half of the year. Additionally, preclinical data for the highly selective CDK9 inhibitor, PRT2527, and the next-generation CDK4/6 inhibitor, PRT3645, will be presented, highlighting their potential therapeutic value in various cancer types. The Company will also host a live webcast to discuss the role of SMARCA in cancer and its clinical relevance.
The development of SMARCA2 degraders and CDK inhibitors represents a significant advancement in targeted cancer therapies. SMARCA2 is part of the chromatin remodeling complex, essential in regulating gene expression and its dysregulation has been implicated in various cancers. An oral SMARCA2 degrader like PRT7732 has the potential to offer a more convenient and less invasive treatment option compared to intravenous therapies, potentially improving patient compliance and quality of life.
Moreover, CDK9 and CDK4/6 are critical enzymes in cell cycle regulation and their inhibition can lead to the suppression of cancer cell proliferation. The preclinical efficacy of PRT2527 and PRT3645, especially in combination with other targeted therapies, could pave the way for more effective treatment regimens. Given the prevalence of lymphoid malignancies and breast cancer, these developments could have a substantial impact on patient outcomes and, by extension, on the business performance of Prelude Therapeutics.
Preclinical data are a cornerstone in the drug development process, providing the first glimpse of a compound's efficacy and safety profile. The acceptance of Prelude's posters at a prestigious conference like AACR indicates peer recognition of the scientific merit of their work. As the company prepares to transition PRT7732 into Phase 1 clinical trials, investors will be closely watching for any data that could signal the compound's viability and potential market impact.
Furthermore, the ability of PRT3645 to penetrate the brain barrier is noteworthy, as it could address a significant unmet need in the treatment of central nervous system-involved malignancies. The combination therapies involving PRT2527 and PRT3645 might offer new hope for patients with refractory cancers. These developments could significantly impact Prelude's valuation and future revenue streams if the clinical trials confirm the preclinical promises.
The oncology market is highly competitive, with numerous companies vying for a share of a growing market driven by an increasing global cancer burden. The introduction of a potentially best-in-class CDK9 inhibitor and a next-generation CDK4/6 inhibitor by Prelude Therapeutics could disrupt existing treatment paradigms if their preclinical advantages translate into clinical benefits. This could lead to a reevaluation of the company's market position and influence investor sentiment.
Strategic partnerships, licensing agreements, or even acquisition interest could arise if these compounds demonstrate significant advantages over existing therapies. The potential for multi-indication treatment options also broadens the market opportunity for these drugs. Investors should monitor the outcomes of the upcoming clinical trials and any strategic moves by Prelude in response to these results.
03/05/2024 - 04:45 PM
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.
Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, “We look forward to sharing data on the preclinical characterization of our lead oral SMARCA2 degrader, PRT7732, which is on track to advance into Phase 1 clinical development in the second half of this year, and to presenting additional preclinical data for our highly selective and potent CDK9 inhibitor, PRT2527, that supports its potential therapeutic value in combination with BTK and BCL2 inhibitors in lymphoid malignancies. For our next generation CDK4/6 inhibitor, PRT3645, we will present preclinical data supporting its potential therapeutic value in combination with other targeted therapies for a range of tumor types in addition to breast cancer.”
Details on the poster presentations are as follows:
Title: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2Presenter : Artem ShvartsbartSession Category: ChemistrySession Title: Targeted Protein DegradationSession Date and Time: Tuesday April 9, 2024, 9:00 AM - 12:30 PMLocation: Poster Section 21Poster Board Number: 4Published Abstract Number: 4503
Title: PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid MalignanciesPresenter: Norman FultangSession Category: Experimental and Molecular TherapeuticsSession Title: Novel Biologic Therapies and Therapeutic TargetsSession Date and Time: Tuesday April 9, 2024, 1:30 PM - 5:00 PMLocation: Poster Section 27Poster Board Number: 14Published Abstract Number: 5966
Title: The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination with Other Targeted Therapies in Preclinical Models of Breast Cancer, CRC and NSCLCPresenter: Yue ZouSession Title: Pharmacologic Targeting of Cell Cycle ProteinsSession Date and Time: Tuesday April 9, 2024, 1:30 PM - 5:00 PMLocation: Poster Section 18Poster Board Number: 10Published Abstract Number: 5710
On Friday, April 5 at 7:00 p.m. PT, the Company will host a live webcast “Let’s Talk SMARCA” Teach-In on the basic science behind the role of SMARCA in the chromatin remodeling complex and its potential clinical relevance in multiple cancers. To attend in person or via webcast, visit: https://edge.media-server.com/mmc/p/5dwkjbcy . A replay of the webcast will be available on the Prelude website for 90 days.
About Prelude
Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes: an IV administered, potent and highly selective SMARCA2 degrader, PRT3789, a preclinical oral SMARCA2 selective degrader, PRT7732, a potent and highly selective CDK9 inhibitor, PRT2527, and a next generation CDK4/6 inhibitor, PRT3645.
For more information, visit our website and follow us on LinkedIn and Twitter .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for initial proof-of-concept data and clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway into 2026. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
Investor Contact: ltrickett@preludetx.com
Media Contact: Helen@ShikCommunications.com
What posters have been accepted for presentation at the AACR Annual Meeting 2024 by Prelude Therapeutics Incorporated?
Three posters with preclinical data on the Company's highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor, and next-generation CDK4/6 inhibitor have been accepted for presentation at the AACR Annual Meeting 2024.
When is the AACR Annual Meeting 2024 taking place?
The AACR Annual Meeting 2024 is scheduled to take place from April 5 to 10, 2024.
Who is the Chief Scientific Officer of Prelude Therapeutics Incorporated?
Peggy Scherle is the Chief Scientific Officer of Prelude Therapeutics Incorporated.
What is the lead oral SMARCA2 degrader of Prelude Therapeutics Incorporated?
The lead oral SMARCA2 degrader of Prelude Therapeutics Incorporated is PRT7732.
When will PRT7732 advance into Phase 1 clinical development?
PRT7732 is on track to advance into Phase 1 clinical development in the second half of this year.
What is the potentially best-in-class CDK9 inhibitor of Prelude Therapeutics Incorporated?
The potentially best-in-class CDK9 inhibitor of Prelude Therapeutics Incorporated is PRT2527.
What is the next-generation CDK4/6 inhibitor of Prelude Therapeutics Incorporated?
The next-generation CDK4/6 inhibitor of Prelude Therapeutics Incorporated is PRT3645.
What will be discussed in the live webcast hosted by Prelude Therapeutics Incorporated?
The live webcast will discuss the role of SMARCA in the chromatin remodeling complex and its potential clinical relevance in multiple cancers.
